Breaking News, Collaborations & Alliances

AbelZeta, Janssen Amend CAR-T Deal

Janssen will have the option to obtain exclusive commercialization rights in China for C-CAR039 and C-CAR066 for the treatment of NHL.

AbelZeta Pharma, Inc., a global clinical-stage biopharmaceutical company, amended its worldwide collaboration and license agreement with Janssen Biotech, Inc., a Johnson & Johnson company. Under the amended agreement, Janssen will have the option to obtain exclusive commercialization rights in China for CD20-directed chimeric antigen receptor T (CAR-T) C-CAR039 and C-CAR066, which are being studied for the treatment of Non-Hodgkin Lymphoma (NHL). Janssen will pay AbelZeta Pharma an option...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters